Amphion Innovations plc Second DataTern Patent Approved

Amphion Innovations plc Second DataTern Patent Approved

Amphion Innovations plc, the developer of medical and technology businesses, is pleased to announce today that its wholly-owned subsidiary, DataTern Inc., has received from the United States Patent and Trademark Office ("USPTO") a Notice of Intent to Issue Ex Parte Reexamination Certificate confirming the patentability of the original 20 claims of the U.S. Patent No. 5,937,402 ("402") as well as three clarifying patent claims added during the reexamination.  This determination by the USPTO is an important part of further validating our outstanding patents.

In 2009, Amphion announced that the 6,101,502 ("502") patent had successfully completed reexamination by the USPTO and was reissued with all 18 original claims intact and 26 new ones added.   The positive outcomes for both reexaminations increase our confidence in the fundamental strength of these technologies and patents.    DataTern is currently enforcing its patents against companies that are using the patented technology without DataTern's permission.

DataTern, a wholly-owned subsidiary of Amphion Innovations plc., fosters innovation by helping companies develop and commercialise promising technologies, including in the IT and healthcare sectors. DataTern is represented by McCarter & English LLP in Boston.

Richard Morgan, CEO of Amphion, commented: "This outcome is an important validation of the strength of DataTern's IP.  Both key patents 402 and 502 have now been reexamined by the USPTO with positive outcomes. The result is another important milestone for the development of our IP program with our new legal partners McCarter & English LLP. We look forward with increased confidence to positive results in the  existing cases and gaining additional licensing revenues from these and other companies using our technology in the future."

No Comments

Post a Comment